LPL Financial’s Cardiol Therapeutics CRDL Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$29.3K Buy
17,650
+5,040
+40% +$8.03K ﹤0.01% 6184
2026
Q2
$13.4K Buy
+12,610
New +$16K ﹤0.01% 6150
2025
Q3
– Sell
-15,210
Closed -$20.7K – 5842
2025
Q2
$20.7K Buy
+15,210
New +$17.7K ﹤0.01% 5470
2025
Q1
– Sell
-18,310
Closed -$23.4K – 5388
2024
Q4
$23.4K Buy
18,310
+5,000
+38% +$8.43K ﹤0.01% 5180
2024
Q3
$26.4K Buy
+13,310
New +$27.6K ﹤0.01% 5061
2022
Q3
– Sell
-10,230
Closed -$14K – 4435
2022
Q2
$14K Buy
+10,230
New +$14.6K ﹤0.01% 4369

Other funds holding CRDL

LPL Financial's CRDL Position: Q3 2026 in Review

LPL Financial increased its Cardiol Therapeutics (CRDL) stake by 40% in Q3 2026, buying an estimated $8.03K and bringing the position to 17,650 shares worth $29.3K. The position accounts for ﹤0.01% of the portfolio, ranked #6184.

LPL Financial first reported a position in CRDL in Q2 2022 and has held it in 6 quarters since. 59 funds tracked by Wall St. Rank hold CRDL as of Q3 2026.

  • LPL Financial held 17,650 shares of Cardiol Therapeutics worth $29.3K as of Q3 2026.
  • LPL Financial bought 5,040 Cardiol Therapeutics shares in Q3 2026, an estimated $8.03K.
  • Cardiol Therapeutics made up ﹤0.01% of LPL Financial's portfolio in Q3 2026, its #6184 holding.
  • LPL Financial first reported a position in Cardiol Therapeutics in Q2 2022 and has held it in 6 quarters since.
  • 59 funds tracked by Wall St. Rank held Cardiol Therapeutics as of Q3 2026.

Based on LPL Financial's 13F filing for Q3 2026, filed 6 Nov 2026.